med chem of antifungals Flashcards

1
Q

overview of fungi

A

Diverse group of eukaryotes** (> 1.5 million species): rigid cell wall, require organic compounds for both carbon and energy sources, obtain nutrients by absorption, live off decaying matter (saprophytes) or living matter (parasites)
Generally harmless for humans: relatively few are human pathogens (100’s), Most cannot infect humans with normal immune system
Two broad groups:
-Yeast
-Mold (mould)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

increasing fungal infections

A

Parallels increase in number of people who:
-Have immunosuppressive infections
-Are taking immunosuppressive drugs
-Use implanted medical devices
Four species account for ~90% of deaths: Cryptococcus, Candida, Aspergillus, Pneumocystis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

two broad groups of fungi

A

Yeast: Grow as single cells, Divide asexually by budding (fission)
Mold: Filamentous multicellular aggregates (hyphae), Hyphae grow by elongation at their tips, Usually separated into cell-like units by crosswalls called septa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

dimorphic fungi

A

Grow as hyphae at room temperature
Grow as yeast in human tissue or on media at 37 C
Conversion to yeast form appears to be necessary for pathogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

characteristics of pathogenic fungi

A

Able to grow at high temperatures
Able to reach target tissues
-Dissemination in air (spores or similar)
-Penetration of host barriers
-Dissemination in body -Ability to change morphology is key, Many fungal pathogens are thermally dimorphic
Able to digest and absorb components of human tissues
Able to withstand/evade immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

sporulation

A

Reproduction and spread in the environment

Source of infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

classification of fungal infections

A

True vs opportunistic
-True: cutaneous infective, subQ infective or systemic infective
Superficial and cutaneous - diseases are generally cosmetic, not life-threatening
Subcutaneous - fungi are generally implanted in skin, fungal growth produces a lesion
Systemic or invasive - Fungi have invaded the deep tissues, Can be self limiting or cause severe disease with high mortality rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

superficial and cutaneous infections

A

Dermatophytosis
-Classic skin and hair infections (ringworm, athlete’s foot, jock itch, etc.)
-Involve 3 genera of mold that grow on keratin on a living host (Epidermophyton, Trichophyton, and Microsporum)
-Cause a series of conditions referred to as tineas
—Tinea capitis = ringworm of the scalp
—Tinea pedis = athlete’s foot
Onchomycosis
-refers to non-dermatophyte nail infections or to any fungal nail infection caused by any fungus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

systemic invasive infections

A

Examples: Coccidioides, Histoplasma, Blastomyces
Usually begin in lung – asymptomatic, influenza- like, or pneumonia
May disseminate to internal tissues or organs
-Blastomyces – bone, skin, joints
-Histoplasma – gastrointestinal tract, adrenals, bone and skin
Usually asymptomatic and self limiting, but may be severe and life threatening
Immune response is cell mediated
Infection is not communicable
Geographically restricted (endemic fungi)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

histoplasmosis

A
Caused by dimorphic endemic fungi** Histoplasma capsulatum var. capsulatum
Bat or bird droppings
Spores!
Lung is most frequent site of infection
All stages of this disease may mimic tuberculosis
People at risk for disseminated disease 
-Immunosuppressed individuals
-children under 2 years old
-elderly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

blastomycosis

A

Caused by Blastomyces dermatitidis
-Endemic dimorphic fungi
-survives in soil that contains organic debris (rotting wood, animal droppings, plant material)
-infects people collecting firewood, tearing down old buildings, etc.
1-2 cases per 100,000 in endemic areas
50% of primary infections are asymptomatic
Acute pulmonary disease indistinguishable from bacterial pneumonia
Permanent lung damage with chronic disease
Mortality rate is about 5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Coccidioidomycosis

A

Dimorphic fungus Coccidioides immitis
Endemic** in southwest US
Infection begins in lungs after inhaling spores
50% of infections are asymptomatic
Symptoms are flu-like
Severe pulmonary disease may develop in HIV-infected persons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Opportunistic fungal infections

A

Not considered true pathogens - do not cause disease in immunocompetent people; low virulence
Most common: Candida, Cryptococcus, Pneumocyctis, Aspergillus, Mucomorales
Risk factors: immunosuppression, major burn wounds or trauma, central venous catheters, broad-spectrum antibiotics, Diabetes, renal insufficiency requiring dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Candidiasis

A

Caused by Candida albicans and other species of Candida
Classified as a yeast
Part of the normal human flora
Occurs when: members of the normal flora are suppressed, host immune response is diminished, especially neutrophil function
Can be localized to mucous membrane or may be invasive
-Candidemia – blood stream infection
-visceral infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

scope of the problem

A

Most common fungal pathogens - 8 cases per 100,000 in the general population
75% of women have at least one bout of vulvovaginal candidiasis (VVC)
> 90% of people infected with HIV who are not receiving therapy develop oropharyngeal candidiasis
4th most common bloodstream infection among hospitalized patients in the U.S.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

diseases caused by candida

A

Can infect healthy and immunocompromised people
Cutaneous candidiasis
-diaper rash, jock itch, athlete’s foot
-key factor: prolonged exposure of normally dry skin to moisture
Esophagitis - HIV patients
Onchomycosis (nail)
Oropharyngeal (thrush)
Vulvovaginitis: Women treated with broad-spectrum antibiotics, Pregnancy, Diabetes
Candidemia and invasive (Systemic) infections
-Not typically diseases of healthy individuals
-Can involve virtually any organ
-Mortality ranges from 30-40%
-Responsible for the largest number of deaths from fungal infections
Most Candida infections are mucocutaneous and do not cause mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

aspergillosis

A

Large spectrum of diseases caused by many species of Aspergillus
Hyphal growth
Three disease states:
-Opportunistic infections (inhaled into the respiratory tract, characterized by angioinvasion, hemorrhage and tissue infarction, especially in the lungs)
-Allergic states
-Toxicoses** - some species produce toxins (aflatoxin)
Risk factors
-Prolonged granulocytopenia & organ transplant
-Not HIV
High mortality rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cryptococcosis

A

Most cases caused by Cryptococcus neoformans
-Exists only as a yeast
-Found in soil worldwide - usually with bird droppings (especially pigeons)
-Cryptococcus gattii outbreak in NW
Wide polysaccharide capsule*
Acquired by inhalation
Presents most commonly as chronic meningitis
85% of cases occur in HIV-infected persons (2-7 cases per 1000 AIDS patients)
12 % fatality rate in AIDS patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

antifungal drugs: polyenes

A

i.e. amphotericin B
Main features
-natural product - produced by Streptomyces nodus
-Amphoteric - has both an acidic and basic groups
-Contains a lipophilic polyene region (bottom) and a hydrophilic polyalcohol region (top) - amphiphilic
-Macrolide ring
-Fungicidal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

amphotericin B MOA

A

Amphotericin B binds to ergosterol in cell membrane - predominant sterol in fungal cell membranes - leakage of intracellular cations and proteins
Reason for specificity: mammalian and bacterial cell membranes contain cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

amphotericin B - PKs

A

Poorly absorbed from GI tract
Oral amphotericin B only effective for GI infections
Intravenous injection required for systemic infection
Cerebrospinal levels 2-3% of blood levels
-intrathecal therapy needed for fungal meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

amphotericin B AEs

A

Toxicity is low enough to allow use, but still very toxic
Infusion-related
-Fever, chills, muscle spasms, vomiting, headache and hypotension
-Can be ameliorated by reducing rate of infusion
-Premedication with diphenhydramine and/or acetaminophen
Renal damage
-Occurs in nearly all patients
-Reversible component - reduced renal perfusion
-Irreversible component - renal tubular injury - Usually occurs after prolonged (>4 g) administration
Liver abnormalities occasionally observed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

therapeutic applications

A

Systemic infections
-Amphotericin B
—broad spectrum antimycotic (Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, and Aspergillus fumigatus)
—Some fungi are naturally resistant
—Drug of choice for life-threatening fungal infections
-Intravenous administration over 1-4 hours
• Superficial fungal infections
-Nystatin - polyene drug similar to amphotericin B
—Too toxic for systemic administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

amphotericin formulations

A

Conventional amphotericin B (C-AMB; Fungizone™)
-Available since 1960
-Colloidal suspension
-Deoxycholate (a bile salt) used as the solubilizing agent
Lipid formulations
-Amphotericin B colloidal dispersion (ABCD; Amphotec™)
-Liposomal amphotericin B (L-AMB; Ambisome™)
-Amphotericin B Lipid Complex (ABLC; Abelcet™)

25
Q

lipid formulations of amphotericin

A
Lipid formulations reduce nephrotoxicity
Act as reservoir of amphotericin
-Lipids have intermediate affinity for amphotericin - higher than cholesterol, but lower than ergosterol
Formulations use different lipids
Ambisome also reduces infusion toxicity
-Only AmBisome uses true liposomes
ABCD has less neprotoxicity but potentially more fever
COST!!
26
Q

ergosterol synthesis pathway

A

Most fungi have ergosterol in their cell membranes
Plays same role as cholesterol in mammalian cell membranes
-Very similar pathways for synthesis

27
Q

antifungal drugs: allyamines

A

terbinafine
Mode of action: disrupts ergosterol synthesis
Mechanism of action: inhibits squalene epoxidase

28
Q

antifungal drugs: terbinafine

A

Fungicidal - Death results from accumulation of squalene, not loss of ergosterol
2,500 fold selectivity for fungal enzyme compared to mammalian enzyme
Mainly effective against dermatophytes, especially onchomycoses
-More effective, less toxic, & requires shorter treatment than griseofulvin
Available for oral and topical administration
-ringworm, pityriasis versicolor, and fungal nail infections
-Lamisil (and several other brand names)
Tolnaftate (Tinactin), butenafine (Lotrimin Ultra), and naftifine (Lotrimin) are chemically similar
Same mechanism
Only available in topical preparations
Butenafine has superior efficacy against dermatophytes, Candida, Cryptococcus, Aspergillus
-Also has anti-inflammatory properties

29
Q

antifungal drugs: azoles

A
Largest class of antimycotics: >20 drugs
Key feature: 5-membered aromatic ring
Mechanism of action
-Inhibition of 14 a-demethylase
Fungistatic
30
Q

azoles MOA

A

Azoles inhibit the binding and activation of molecular oxygen by cytochrome P450 - Inhibit the conversion of lanosterol to ergosterol - create toxic sterols which accumulate in cell membrane

31
Q

azole selectivity

A

Humans use same enzyme to make cholesterol for our cell membranes
Fungal enzyme more sensitive
-Ketoconazole IC50 for Candida enzyme = 10^9 M
-Ketoconazole IC50 for human enzyme = 10^6 M
-However, azoles inhibit other mammalian cytochrome P450s

32
Q

azole metabolism

A

In general, azoles are metabolized extensively by liver cytochrome P450s
All metabolites are inactive
Only those azoles with reduced metabolism are used for systemic infection
-Ketoconazole
—First orally active azole
—Clinically important interactions with human CYP450s
-Fluconazole
-Itraconazole
-Voriconazole
-Posaconazole
-Isavuconazole

33
Q

early azole antifungals

A

Clotrimazole and miconazole were the first described azole antifungals (1969)
Differ in distance of azole group from asymetric carbon
Miconazole used as basis for later generation azoles
Alterations change
-Spectrum of activity
-Interaction with CYPs
-Route of elimination

34
Q

ketoconazole

A

First azole with sufficient oral bioavailability to be used clinically for deep tissue infections
Based on miconazole
-Dioxolane ring on asymetric carbon
-Reduced metabolism by CYP3A

35
Q

itraconazole

A

Based on ketoconazole

  • Triazole instead of imidazole
  • Modified substituent on dioxolane ring
  • Improved specificity for fungal P450 enzyme
36
Q

Posaconazole

A

Derived from itraconazole
-Has furan ring – alters and increases spectrum of activity
-F replaces Cl
Broad spectrum activity
Available for oral (as suspension) and IV admin

37
Q

Isavuconazole

A

Structurally similar to voriconazole
Broad spectrum activity
-Similar to voriconazole, but also Zygomycetes
Water soluble prodrug
-Cyclodextrin not required for solubility
-Reduced nephrotoxicity relative to voriconazole
Long half life

38
Q

azole drugs and CYP450

A

In general, azole antifungals are metabolized by and inhibit liver CYP450 enzymes**

  • Triazole concentrations can be increased by other drugs metabolized by this pathway
  • Concentration of drugs metabolized by CYP enzymes can be increased
  • Inducers of CYPs can decrease triazole levels - Rifampicin - potent inducer
39
Q

ketaconazole and CYP450

A

Ketoconazole is a potent inhibitor of CYP3A4
Drug interactions
-Inhibits metabolism of terfenadine (Seldane) and cisapride (both removed from US market)
-Increases area under curve and half life of triazolam
-Increases bioavailability of cyclosporin
-CYP3A4 inducers (rifampin, etc.) reduce ketoconazole levels

40
Q

azole metabolism

A

Itraconazole - extensively metabolized by CYP3A4 in liver
Fluconazole - 80 % excreted by kidney unchanged
Voriconazole - metabolized extensively in liver by CYP2C19 > CYP3A4&raquo_space; CYP2C9
-CYP2C19 polymorphisms can alter levels
Posaconazole - metabolized in liver by glucuronidation

41
Q

fluconazole clinical uses

A

High solubility, bioavailability
Penetrates CSF
Widest therapeutic index of the azoles
Spectrum of activity
-Good activity against C. albicans and many other Candida species - Most commonly used agent for mucocutaneous Candida
-Some Candida species are naturally resistant (C. krusei, C. glabrata)
-Cryptococcus neoformans - Azole of choice for treatment and prophylaxis of cryptococcal meningitis
-No therapeutically useful activity against histoplasmosis, blastomycosis, or sporotrichosis
-No activity against Aspergillus or filamentous fungi

42
Q

Itraconazole clinical uses

A

Similar spectrum to fluconazole, plus aspergillus
-Not as broad as voriconazole, posaconazole, or isavuconazole
Azole of choice for Histoplasma, Blastomyces, and Sporothrix
Extensively used for dermaphytoses and onchomycoses
Variable absorption
Bad taste

43
Q

Voriconazole clinical uses

A

Highly soluble
High oral bioavailability
CSF levels ~1/2 of plasma levels
Active against Candida species, including some fluconazole-resistant strains
Extended spectrum of activity against yeasts, Cryptococcus and molds, including Aspergillus
Active against some fluconazole-resistant Candida spp.
May be more effective against Aspergillus than amphotericin B
Teratogenic in animals and is contraindicated in pregnancy (Category D)
Visual disturbances in 30% of patients - Flickering lights or zigzag lines

44
Q

Posaconazole clinical uses

A

Approved in May 2007
Broadest spectrum azole to date
Spectrum of activity similar to voriconazole - Better activity against filamentous fungi such as zygomycetes

45
Q

Isavuconazole clinical uses

A

Spectrum of activity similar to voriconazole
Approved for treatment of invasive aspergillosis and mucormycosis
water-soluble intravenous formulation
oral formulation has high bioavailability
few serious adverse effects
fewer drug–drug interactions than voriconazole

46
Q

topical azoles for superficial fungal infections

A
Clotrimazole and miconazole most common
Ketoconazole available as shampoo
Newest topical azoles
-Luliconazole
-Efiniconazole – First topical treatment for onychomycosis - as effective as oral itraconazole
47
Q

antifungal drugs: Echinocandins

A
Second newest class of antifungals
Lipopeptides**
-Synthetically modified fungal compounds
-Caspofungin - Glarea lozoyenisi
-Micafungin - Coleophoma empedri
-Anidulafungin - Aspergillus nidulans
All must be administered by IV
Cyclic hexapeptides with long, modified fatty acid side chains
48
Q

echinocandins

A

Inhibit synthesis of b(1-3)glucan - cell wall component – inhibits
-b(1-3) glucan synthase is the target enzyme
Reason for selectivity
-Mammalian cells lack this activity
Fungicidal
Broad spectrum activity
-Synergistic with voriconazole and amphotericin B
No cross resistance with other antifungals

49
Q

echinocandins - clinical uses

A

Caspofungin
-Disseminated and mucocutaneous candida
-Salvage therapy in patients with aspergillosis who fail to respond to amphotericin B
Micafungin
-mucocutaneous candida
-Candida prophylaxis in bone marrow transplant patients
Anidulafungin
-Esophogeal candidiasis
-Invasive candidiasis
-Has longest half life and no known drug interactions
Micafungin and anidulafungin are associated with fewer adverse events

50
Q

echinocandins metabolism

A
NOT metabolized by liver CYPs
-Anidulafungin and micafungin generally have fewer adverse effects
Degraded in blood and in tissues
-Ring opening
-Peptide hydrolysis
51
Q

antifungal drugs: flucytosine

A
Mode of action: antimetabolite
Mechanism:
-Inhibits thymidylate synthase
-Interferes with protein synthesis
Reason for specificity: mammalian cells are unable to convert flucytosine to active metabolite
Synergizes with amphotericin B
52
Q

flucytosine MOA

A

Flucytosine is first converted by cytosine deaminase to 5-fluorouracil (5-FU)
phosphorylated to form 5-FdUMP
5-FdUMP mimics dUMP
5-FdUMP is a substrate, a competitive inhibitor, and a suicide inhibitor of thymidylate synthase
In 5-FdUMP, there is an F in place of H found in dUMP
F is the most electronegative atom -> cannot be eliminated
TS trapped in an inactive form and cannot react with dUMP
No dTMP can be produced, and this inhibits DNA synthesis

53
Q

flucytosine PKs

A

Available only in oral form
Penetrates well into all fluid compartments including cerebrospinal fluid
Removed by kidney
Renal impairment can lead to toxicity

54
Q

flucytosine AEs

A

Intestinal flora can metabolize to 5-FU - anti cancer drug

Monitor levels when combined with amphotericin B (why?)

55
Q

flucytosine clinical uses

A

Limited spectrum of activity
-Cryptococcus neoformans
—Combined with amphotericin B for crytococcal meningitis
-Some Candida species
-Aspergillus
-Most filamentous fungi are not susceptible to 5-FC
Narrow therapeutic window
-Concentration too high - toxicity
-Concentration too low - resistance
Nearly always administered with amphotericin B or fluconazole

56
Q

antifungal drugs: griseofulvin

A

Discovered in 1939
Produced by a strain of Penicillium
Disrupts fungal microtubules
Fungistatic
Must be given orally - Becomes incorporated in keratin precursor cells
Used for dermatophytes
Inactive against yeast, mold, and dimorphic fungi - not absorbed

57
Q

Tavaborole

A
Newest class of antifungal drugs
Mechanism – inhibits leucyl transfer RNA synthetase (LeuRS)
-Inhibits protein synthesis
Boron is essential for activity
Topical treatment of onychomycosis
58
Q

Resistance to antifungal agents

A

Natural resistance (intrinsic) vs. induced (acquired)
Candida krusei - intrinsically resistant to fluconazole; reduced susceptibility to flucytosine and amphotericin B
Candida glabrata - multiazole, echinocandin, and multidrug resistance
-constitutive expression of drug resistance pathways
Aspergillus terreus - intrinsically resistant to amphotericin
Antifungal treatment has altered the types of fungi associated with infection
-C. glabrata is 2nd most commonly isolated Candida species

59
Q

Resistance to antifungal agents

A

Natural resistance (intrinsic) vs. induced (acquired)
Candida krusei - intrinsically resistant to fluconazole; reduced susceptibility to flucytosine and amphotericin B
Candida glabrata - multiazole, echinocandin, and multidrug resistance
-constitutive expression of drug resistance pathways
Aspergillus terreus - intrinsically resistant to amphotericin
Antifungal treatment has altered the types of fungi associated with infection
-C. glabrata is 2nd most commonly isolated Candida species
Acquired resistance not transferred between strains as in bacteria
Azoles
-Target site alteration – accounts for most resistant strains
-Reduced drug concentration via efflux pumps
-Target enzyme upregulation
-Development of bypass pathways
-Increasingly common, esp. Aspergillus
Polyenes - reduced ergosterol content
Echinocandins - target site mutations; rare
Flucytosine - cytosine deaminase or UPRT (cytosine permease)
Allylamines and griseofulvin - not well characterized